This is a working overview of GW501516, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2025-10-25. Anything still debated is marked as such rather than presented as settled.
Cardarine is prohibited in competitive sport under the World Anti-Doping Agency code, where it is classified as a metabolic modulator. It is not approved as a prescription medicine in the United States, European Union, or other major markets. Regulatory action has focused on its presence in sports and in products marketed as research chemicals. Because it has no accepted medical indication, supply is often unregulated. This status creates legal and safety uncertainties for anyone who encounters the substance.
Anti-doping laboratories detect GW501516 and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is the most common matrix, though blood and dried blood spots may also be used in some programs. Detection depends on factors such as dose, timing, metabolism, and the sensitivity of the assay. Published methods describe limits of detection in the low nanogram per milliliter range for related compounds. Exact detection windows are not fixed for all situations and remain an area of ongoing study.
Laboratory detection of cardarine typically involves sample preparation followed by chromatographic separation and mass spectrometric identification. Urine is the most common matrix for anti-doping tests, though blood and hair have also been explored. Methods can target the parent compound or its metabolites, depending on the expected window of detection. Reference standards are required for accurate quantification. Matrix effects and dilution can influence results, so laboratories use internal standards and validation protocols. The exact detection window varies with dose, route, and individual metabolism.
A common misconception is that cardarine has been proven safe for human use. In reality, human clinical data are limited, and long-term animal studies have raised concerns about cancer. Another misconception is that it is a supplement or vitamin-like compound. It is a synthetic research chemical with no approved medical indication. Scientific discussion often focuses on its mechanism and detection rather than therapeutic use. Regulatory and anti-doping literature treats it primarily as a prohibited substance.
Cardarine is explicitly prohibited by the World Anti-Doping Agency under the class of PPARδ agonists. Its presence in urine or blood samples can be detected using mass spectrometry-based methods, often liquid chromatography-tandem mass spectrometry. Athletes who test positive may face sanctions, including bans from competition. The compound is also regulated as a prescription-only or unapproved drug in many countries. Enforcement varies by jurisdiction, and some regions treat it as a controlled substance. Online sales may occur despite these restrictions, creating quality and legal risks.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Prohibited in sport | Listed by WADA as a metabolic modulator. |
| Approved medical use | None in major jurisdictions | Not a registered drug. |
| Common test matrix | Urine | Most anti-doping samples use urine. |
| Typical detection method | LC-MS/MS | Detects parent compound and metabolites. |
| Reference standard storage | -20 °C, desiccated | Typical for analytical standards. |
Legal status varies by country. In some places, cardarine is controlled under medicines or psychoactive substances laws; in others, it may be sold with minimal oversight as a research chemical. Customs agencies have intercepted shipments, and several national health agencies have issued warnings about products marketed for bodybuilding or performance enhancement. The lack of a standardized pharmaceutical supply means identity, purity, and contamination levels can differ widely between samples. These factors make cardarine a regulatory and public health concern rather than a conventional prescription drug.
Cardarine is a common name for GW501516, a synthetic compound first described in the 1990s as a selective agonist of the peroxisome proliferator-activated receptor delta. It was studied in preclinical models for metabolic and cardiovascular conditions, but it has not been approved as a medicine in the United States, Europe, or other major jurisdictions. Retail products labeled as cardarine are generally research chemicals or supplements, not pharmaceutical formulations. Because human safety and efficacy data remain limited, regulatory agencies treat it as an unapproved substance rather than a therapeutic product.
Sporting authorities added GW501516 to prohibited lists after it appeared in athlete samples and online markets. The World Anti-Doping Agency classifies it as a hormone and metabolic modulator, and its use can lead to an anti-doping rule violation. Some early laboratory work suggested effects on fatty acid oxidation and endurance-related metabolism in animals, but those findings do not establish safe or effective use in people. Reports of adverse events in humans are scarce and often anecdotal, which complicates risk assessment.
Clinical development stopped after rodent studies showed tumors at multiple sites. Whether those findings predict human cancer risk remains an open question, but they led sponsors to discontinue programs. Human safety data are limited to small, short-term studies that were not designed to assess cancer risk. Reported effects in those studies included changes in blood lipids, but the evidence is insufficient for medical use. Long-term consequences of nonmedical use are not well characterized. Questions about dose, duration, and individual susceptibility remain unresolved.
Cardarine is a common name for GW501516, an investigational compound developed in the 1990s for metabolic conditions. It acts as an agonist at peroxisome proliferator-activated receptor delta, a nuclear receptor involved in lipid and energy metabolism. The compound is frequently mislabeled as a selective androgen receptor modulator, or SARM, but its molecular target is different. GW501516 reached early clinical testing before development was discontinued. It has no approved therapeutic use in any country. The name cardarine is not a formal international nonproprietary name.
The pharmacological interest in cardarine centers on PPARδ activation and its downstream effects on lipid handling and mitochondrial function. In animal studies, PPARδ agonists have been associated with changes in exercise endurance and fatty acid utilization, though results vary by model and protocol. Human data remain sparse, and the absence of large controlled trials limits conclusions about efficacy. Researchers often describe the compound as a tool for probing PPARδ biology rather than a proven therapeutic agent.
Safety discussions about cardarine frequently cite rodent carcinogenicity findings reported in the 2000s. In those studies, treated animals developed tumors at multiple sites, leading sponsors to discontinue clinical development. The relevance of these findings to humans has not been resolved, but they are a major reason the compound is not approved. Current literature emphasizes uncertainty about long-term effects and the risks of unregulated use. Regulators and health agencies have not established a safe human exposure level.
Cardarine is a synthetic compound also known as GW501516, GW-501516, and sometimes endurobol. It was developed as a selective agonist of peroxisome proliferator-activated receptor delta, a nuclear receptor involved in fatty acid oxidation and energy metabolism. The compound was studied in preclinical models for metabolic and cardiovascular conditions, but it did not become a marketed human medicine. In regulatory and anti-doping contexts, it is treated as a prohibited substance rather than a licensed medicine.
In the fitness and bodybuilding literature, cardarine is frequently discussed as an endurance agent or fat-loss compound, although such claims are not supported by robust clinical evidence. Online descriptions often mix animal data, user anecdotes, and marketing language. Researchers who study PPARδ agonists distinguish between receptor activation in controlled experiments and unsupervised use of unverified products. The latter introduces unknown purity, dose, and interactions, making reported experiences difficult to interpret scientifically.
GW501516 acts as an agonist at peroxisome proliferator-activated receptor delta, a nuclear receptor involved in transcription of genes related to lipid handling and energy use. Activation of PPARδ can shift skeletal muscle toward greater fatty acid oxidation in animal models, which is one reason it drew interest for metabolic disease and exercise research. The exact downstream effects depend on tissue, species, dose, and duration. Human data are sparse, so many proposed benefits remain hypotheses rather than established clinical outcomes.
Thomas Powers, "The Nuclear Worrier" (review of Daniel Ellsberg, The Doomsday Machine: Confessions of a Nuclear War Planner, New York, Bloomsbury, 2017, ISBN 9781608196708, 420 pp.), The New York Review of Books, vol. LXV, no. 1 (18 January 2018), pp. 13–15. "Presidency in the Nuclear Age", conference and forum at the JFK Library, Boston, October 12, 2009. Four panels: "The Race to Build the Bomb and the Decision to Use It", "Cuban Missile Crisis and the First Nuclear Test Ban Treaty", "The Cold War and the Nuclear Arms Race", and "Nuclear Weapons, Terrorism, and the Presidency". Tom Stevenson, "A Tiny Sun" (review of Fred Kaplan, The Bomb: Presidents, Generals, and the Secret History of Nuclear War, Simon and Schuster, 2021, 384 pp.; and Keir A. Lieber and Daryl G. Press, The Myth of the Nuclear Revolution: Power Politics in the Atomic Age, Cornell, 2020, 180 pp.), London Review of Books, vol. 44, no. 4 (24 February 2022), pp. 29–32. "Nuclear strategists systematically underestimate the chances of nuclear accident... [T]here have been too many close calls for accidental use to be discounted." (p. 32.) Jacobsen, Annie (2024). Nuclear War: A Scenario. Hypothetical minute-by-minute examination of how a nuclear first strike could escalate to global thermonuclear war within 72 minutes, based on interviews with military officials and declassified documents. Lee Billings, "The Quest for a Theory of Everything: A Breakthrough Prize winner warns nuclear war could prevent reaching the holy grail of physics", Scientific American, vol. 335, no. 2 (September 2026), pp. 90–93.
=== Ubiquitination and role in development === Cereblon forms an E3 ubiquitin ligase complex with damaged DNA binding protein 1 (DDB1), cullin-4A (CUL4A), and regulator of cullins 1 (ROC1). This complex ubiquitinates a number of other proteins and marks them for degradation via the proteasome. Through a mechanism which has not been completely elucidated, this ubiquitination results in reduced levels of fibroblast growth factor 8 (FGF8) and fibroblast growth factor 10 (FGF10). FGF8 in turn regulates a number of developmental processes, such as limb and auditory vesicle formation. The net result is that this ubiquitin ligase complex is important for limb outgrowth in embryos. At the molecular level, C-terminal cyclic imides have been identified as endogenous degrons recognized by cereblon. Cyclic imides can arise through spontaneous peptide-bond cleavage at asparagine or glutamine residues in aging proteins, and have long been observed in proteins such as α-crystallin. In 2022, C-terminal aspartimide and aminoglutarimide residues were shown to bind the thalidomide-binding domain of cereblon and to function as degrons promoting CRBN-dependent ubiquitination and proteasomal degradation. In the absence of cereblon, DDB1 forms a complex with DDB2 that functions as a DNA damage-binding protein. Furthermore, cereblon and DDB2 bind to DDB1 in a competitive manner.
==== Kansas ==== In 2009, the Kansas Legislature passed a bill that would have required dairies that did not use rBST to print disclaimers on their labels that stated, "The Food and Drug Administration has determined there are no significant differences between milk from cows that receive injections of the artificial hormone and milk from those that do not." The bill was vetoed in the last days of the 2009 legislative session by then-Governor Kathleen Sebelius. The legislature removed the labeling language and passed the bill without the provision.
== Early career == Stansbury began her career as an ecology instructor at the New Mexico Museum of Natural History and Science. As a White House Fellow, she worked as a policy advisor on the Council on Environmental Quality. She was a consultant at Sandia National Laboratories and later served as a program examiner in the Office of Management and Budget during the Obama administration. She worked on the staff of the United States Senate Committee on Energy and Natural Resources and as an aide to Senator Maria Cantwell. Since 2017, she has worked as a consultant and senior advisor at the Utton Transboundary Resources Center of the University of New Mexico.
Sources: en.wikipedia.org
Genetics (from Ancient Greek γενετικός genetikos, "genite" and that from γένεσις genesis, “origin”), a discipline of biology, is the science of heredity and variation in living organisms. Articles (arranged alphabetically) related to genetics include:
== Pathogenesis == The cells of adipose (fat) tissue synthesize hormones known as adipokines. In humans, dysfunction of adipose tissue, even in cases without obesity, has been associated with the development of insulin resistance, hypertension, systemic inflammation, and increased risk of blood clots (thrombosis). The inflammation produced by these hormones are thought to inflame adipose tissue, leading to the production of more adipokines and perpetuation of the cycle, and a constant low-level, pro-inflammatory state. Although it is suspected that a similar mechanism occurs in horses, further research is needed.
In the cobalamins, cobalt normally exists in the trivalent state, Co(III). However, under reducing conditions, the cobalt center is reduced to Co(II) or even Co(I), which are usually denoted as B12r and B12s, for reduced and super reduced respectively. B12r and B12s can be prepared from cyanocobalamin by controlled potential reduction, or chemical reduction using sodium borohydride in alkaline solution, zinc in acetic acid, or by the action of thiols. Both B12r and B12s are stable indefinitely under oxygen-free conditions. B12r appears orange-brown in solution, while B12s appears bluish-green under natural daylight, and purple under artificial light. B12s is one of the most nucleophilic species known in aqueous solution. This property allows the convenient preparation of cobalamin analogs with different substituents, via nucleophilic attack on alkyl halides and vinyl halides. For example, cyanocobalamin can be converted to its analog cobalamins via reduction to B12s, followed by the addition of the corresponding alkyl halides, acyl halides, alkene or alkyne. Steric hindrance is the major limiting factor in the synthesis of the B12 coenzyme analogs. For example, no reaction occurs between neopentyl chloride and B12s, whereas the secondary alkyl halide analogs are too unstable to be isolated. This effect may be due to the strong coordination between benzimidazole and the central cobalt atom, pulling it down into the plane of the corrin ring. The trans effect determines the polarizability of the Co–C bond so formed.
==== Hypogonadism ==== Insufficient or low levels of testosterone in the body can affect the proper functioning of the male reproductive structures and thus lead to decreased secretions or hypospermia. Long-term exposure to drugs with anti-androgen properties (e.g. spironolactone) can also lead to infertility or low volume of semen. Testosterone is produced by the testes and can be used to diagnose hypogonadism.
Bicalutamide is eliminated in similar proportions in feces (43%) and urine (34%), while its metabolites are eliminated roughly equally in urine and bile. The drug is excreted to a substantial extent in unmetabolized form, and both bicalutamide and its metabolites are eliminated mainly as glucuronide conjugates. The glucuronide conjugates of bicalutamide and its metabolites are eliminated from the circulation rapidly, unlike unconjugated bicalutamide. The pharmacokinetics of bicalutamide are not affected by consumption of food, a person's age or body weight, renal impairment, or mild-to-moderate hepatic impairment. However, steady-state levels of bicalutamide are higher in Japanese individuals than in white people.
Sources: en.wikipedia.org
X-ray crystallography studies have been performed to determine the structure of aspartate transaminase from various sources, including chicken mitochondria, pig heart cytosol, and E. coli. Overall, the three-dimensional polypeptide structure for all species is quite similar. AST is dimeric, consisting of two identical subunits, each with approximately 400 amino acid residues and a molecular weight of approximately 45 kD. Each subunit is composed of a large and a small domain, as well as a third domain consisting of the N-terminal residues 3–14; these few residues form a strand, which links and stabilizes the two subunits of the dimer. The large domain, which includes residues 48–325, binds the PLP cofactor via an aldimine linkage to the ε-amino group of Lys258. Other residues in this domain—Asp222 and Tyr225—also interact with PLP via hydrogen bonding. The small domain consists of residues 15–47 and 326–410 and represents a flexible region that shifts the enzyme from an "open" to a "closed" conformation upon substrate binding. The two independent active sites are positioned near the interface between the two domains. Within each active site, a couple arginine residues are responsible for the enzyme's specificity for dicarboxylic acid substrates: Arg386 interacts with the substrate's proximal (α-)carboxylate group, while Arg292 complexes with the distal (side-chain) carboxylate. In terms of secondary structure, AST contains both α and β elements. Each domain has a central sheet of β-strands with α-helices packed on either side.
== See also == Phragmen's voting rules – a ballot load balancing method analogous to the idea of Archimedes' principle. Ship stability – Archimedes's theory of displacement of fluid is a core principle of ship stability. List of eponymous laws
=== Irradiated red blood cells === Even after leucocyte filtration, a residual number of leucocytes remain in the red blood cell concentrate (<1 million per unit). These may be harmful for patients who have an impaired, reduced or not yet fully developed immune system, or if the blood donor and recipient are closely related. Therefore, such patients may be issued irradiated blood components, including irradiated red blood cells. X-ray or gamma sources are usually used for irradiation. When blood components are irradiated, the DNA is destroyed in any remaining white blood cells (leucocytes), which stops the leucocytes from being able to proliferate further. Although efficient in reducing the risk of transfusion reactions including fatal transfusion-associated graft-versus-host disease (TA-GvHD), irradiation is damaging to the red blood cell membrane, which can be seen as increased levels of haemolysis during storage. As a consequence, irradiated red blood cell concentrates are usually given a reduced shelf life. Therefore, irradiation of red blood cell concentrates is commonly only performed on demand or for specific parts of the supply.
== Prevalence == Since there is no regular autoantibody screening, patients with LADA are at risk of being diagnosed with type 2 diabetes, which makes it difficult to estimate the prevalence of LADA. Globally, it is estimated that about 8.5% of adults have some form of diabetes and it is estimated that LADA accounts for about 3-12% of all adult diabetes cases. 2015 estimates suggest that up to 10–20% of people with diabetes have LADA.
== Evolution == Actin and closely related proteins are present in all organisms, suggesting the common ancestor of all life on Earth had actin. Actin is one of the most conserved proteins throughout the evolution of eukaryotes. The sequences of actin proteins from animals and amoebae are 80% identical despite being separated by approximately one billion years of evolution. Many unicellular eukaryotes have a single actin gene, while multicellular eukaryotes often have several closely related genes that serve specialized functions. Humans have six; plants have 10 or more. In addition to actin, eukaryotes have a large family of actin-related proteins, or "Arps", that share a common ancestor with actin and are called Arp1–Arp11, with Arp1 the most closely related to actin, and Arp11 the least. Bacteria encode three types of actin: MreB influences cell shape, FtsA cell division, and ParM separation of large plasmids. Some archaea have a bacteria-like MreB gene, while others have an actin gene that more closely resembles eukaryote actin. The eukaryotic cytoskeleton of organisms among all taxonomic groups have similar components to actin and tubulin. For example, the protein that is coded by the ACTG2 gene in humans is completely equivalent to the homologues present in rats and mice, even though at a nucleotide level the similarity decreases to 92%. However, there are major differences with the equivalents in prokaryotes (FtsZ and MreB), where the similarity between nucleotide sequences is between 40 and 50% among different bacteria and archaea species.
Sources: en.wikipedia.org
Legal status varies by country, but cardarine is not approved as a medicine in major jurisdictions. It is often sold as a research chemical, a category that may not be lawful for human use. Buyers should check local laws and product labels carefully.
Anti-doping laboratories use LC-MS/MS to detect GW501516 and its metabolites, usually in urine. The method can identify the parent compound at low concentrations. Detection windows vary with dose and individual factors.
No, cardarine has no approved medical uses in major jurisdictions. Early research explored metabolic conditions, but those programs were discontinued. It is not a registered treatment for any disease.
Yes, WADA prohibits cardarine as a PPARδ agonist. It appears on the prohibited list and can be detected in urine or blood. Athletes using it risk sanctions.